Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana

Table 3 Immunohistochemistry summary of HIV-1 negative and positive vulva cancer samples

Negative	IHC-LANA	LMP1	Cyc. D1	HPV16-E7	HPV16 E6	p21Waf1/Cip1	VEGF
1	-	+	+	+++	+	+	-
2	-	+	+	-	+	++	+++
3	-	+	-	-	+	-	+
4	+	+	+	+	-	+	++
5	+	+	++	++	-	-	++
6	+	+	++	++	-	-	+++
7	-	+	+	+	+	+	+
8	+	+	+	+	+	-	+
9	-	+	+	+	-	-	+
Total	44%	100%	88%	77%	56%	44%	89%
Positive
1	-	-	+	-	-	-	-
2	+	+	+	+	-	+	+
3	-	-	-	-	-	-	+
4	-	+	+	+	-	+	+
5	-	-	-	+	-	+	++
6	+	+	+	++	+	++	+
7	-	-	-	-	-	-	+
8	+	+	-	+	+	+	++
9	+	+	+	++	+	++	++
10	+	+	-	+	+	+	+
11	+	+	+	+++	-	+++	++
12	+	+	+	+	-	+	++
13	+	+	-	+	-	+	++
Total	61%	69%	54%	77%	31%	77%	92%
OR	1.99	0.01	0.16	1.0	0.35	4.26	1.42
CI	1.13-3.49	0.01-0.18	0.07-0.32	0.51-1.93	0.19-0.63	2.31-7.84	0.54-3.6
P value	0.01	0.001	<0.01	1.00	0.004	<0.001	0.47

Oncogenic viruses identified in each VSCC patient as determined by Immunohistochemistry analysis. Most cases tested positive for KSHV, EBV, Cyclin D1, HPV16-E7, HPV16-E6, p21, and VEGF.

ISSN: 1750-9378